absorb.md

Aithan Shapira

Chronological feed of everything captured from Aithan Shapira.

Optimized For Humans: SE01E03 - Harnessing Human Potential in the Age of AI | with Aithan Shapira

<p>In this conversation, Usha Gubbala and Aithan Shapira explore the intersection of human potential and artificial intelligence in organizational contexts. They discuss the importance of adult development in leadership, the challenges of navigating VUCA (volatile, uncertain, complex, and ambiguous) environments, and the role of AI in decision-making. The dialogue emphasizes the need for human connection and collective intelligence in leveraging AI effectively, while also considering the long-term implications of leadership choices on organizational evolution and shareholder value.</p><p>I hope you enjoy this episode!<br> Give it a like, share, and subscribe to not miss the content coming y...

The Midlife Chrysalis: Losing Everything to Find Purpose: Aithan Shapira’s Midlife Shift

<p>What if losing everything was the only way to truly find yourself?</p><p>MIT lecturer and artist Aithan Shapira shares how the collapse of his art career became the catalyst for profound reinvention. </p><p>He explains why midlife isn’t about decline but transformation , a time to practice letting go, reframe purpose, and reconnect with what matters most. </p><p>If you’re in a season of change, this episode will help you see midlife as your greatest canvas yet. </p><p><br /></p><p>Timestamps:</p><p>00:00 Intro</p><p>01:17  Meet Aithan Shapira</p><p>04:05 Living Betwee...

Aithan Shapira | limeSHIFT

Aithan Shapira's paintings and prints are the result of taking the natural world apart and putting it back together confronting all perspectives.

About Fourth Space Design - Medium

Srini Pillay, M.D., a Harvard-trained psychiatrist and brain researcher and MIT's Aithan Shapira with a Ph.D. in creativity have joined forces to bring you ...

Aithan Shapira - HATCH

Aithan Shapira ... Artist, Dad, Lecturer @ MIT Sloan, Founder @ Making to Think, a pedagogy for change that's enabling organizations, governments, and Fortune 100 ...

CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma

Children with relapsed or refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL) have a poor prognosis with approved therapies. Chimeric antigen receptor (CAR)-T cells are approved for adults with R/R B-NHL, but pediatric data is lacking. We report on 13 children with R/R mature B-NHL enrolled on a clinical trial for CD19 CAR-T cells harboring CD28 costimulation. Twelve patients were infused with CAR-T cells, and one had progressed and died prior to infusion. Toxicities included cytokine release syndrome in 8 patients and neurotoxicity in 6, including two patients with grade 4 neurotoxicity. All patients responded to CAR-T cells, including a complete response in 6, complete metabolic response in 2 and partial response in four. The median event-free survival was 15.2 months and median overall survival was not reached. Outcome differed by disease type, as most patients with primary mediastinal B-cell lymphoma had long term remissions, while only two of seven patients with Burkitt lymphoma were long term survivors. Thus, initial response may suffice for certain patients, but further consolidative strategies should be studied in patients with R/R Burkitt lymphoma.